Mitochondrial dysfunction in aging

Mitochondrial dysfunction in aging refers to the progressive loss of mitochondrial respiratory capacity, genome integrity and quality control that accompanies age in most tissues studied. The Hallmarks of aging framework classes it as an antagonistic hallmark, meaning that the underlying responses protect at low intensity and do damage when chronic. The mechanism was long assumed to be self-amplifying oxidative damage, an explanation that has not survived the experiments designed to test it.

§What declines

Mitochondria generate most cellular ATP through oxidative phosphorylation. They also buffer calcium, synthesize iron-sulfur clusters and steroid hormones, and control the intrinsic apoptosis pathway. Each carries multiple copies of a circular genome of roughly 16.5 kilobases encoding 37 genes, 13 of which are protein subunits of the respiratory chain; the remaining thousand-odd mitochondrial proteins are encoded in the nucleus and imported.

With age, measured respiratory capacity per unit of mitochondrial mass falls in muscle, liver and brain. Mitochondrial morphology becomes more heterogeneous, membrane potential declines in a subset of organelles, and damaged mitochondria are cleared more slowly. Aged human skeletal muscle contains individual fibres that lack cytochrome c oxidase activity, each traceable to a clonally expanded mitochondrial DNA deletion. Comparable clonal expansions of mtDNA deletions accumulate in substantia nigra neurons.¹ These are focal failures, cell by cell, and not a uniform dimming across the organism.

§The free-radical theory and its decline

Denham Harman proposed in 1956 that aging results from cumulative damage by free radicals produced during normal metabolism, and in 1972 he placed the main source in mitochondria.² The theory linked metabolic rate, damage and lifespan in one causal chain, and it dominated the field for four decades. It also made a clear prediction: reducing oxidative damage should extend lifespan.

1. 1956
   Free-radical theory proposed
   Denham Harman argues that oxygen radicals produced by metabolism damage cells cumulatively and cause aging.
2. 2004-2005
   Mutator mice
   Mice carrying a proofreading-deficient mitochondrial polymerase accumulate mtDNA mutations and show premature aging phenotypes, at mutation loads far above those seen in normal aging.
3. 2005
   One clean positive
   Targeting catalase to mitochondria extends median mouse lifespan by roughly a fifth, the strongest single result supporting the oxidative theory.
4. 2007-2011
   Antioxidant trials fail
   Meta-analyses of antioxidant supplement trials find no mortality benefit, and vitamin E is associated with increased prostate cancer risk in a large prevention trial.
5. 2009
   Genetic tests come back negative
   A review of mouse models altering antioxidant enzymes finds that most changes to oxidative defences do not alter lifespan.
6. 2013
   Mutation signature reinterpreted
   Sequencing of aged human brain shows mtDNA mutations carry a replication-error signature rather than an oxidative-damage signature.

Nearly every direct test failed. In mice, overexpressing or deleting superoxide dismutases and glutathione peroxidases generally changed markers of oxidative damage without changing lifespan.³ Large randomized trials and meta-analyses of antioxidant supplements found no reduction in all-cause mortality, with signals of harm for some agents.⁴ Long-lived species do not consistently produce fewer radicals. Naked mole-rats carry high levels of oxidative damage yet live an order of magnitude longer than mice of similar size, a comparison that features in the literature on negligible senescence.

The interpretation that replaced the theory is mitohormesis. In this view, modest levels of reactive oxygen species act as signals that trigger adaptive responses, and blunting them removes a stimulus the cell needs. In Caenorhabditis elegans, increasing mitochondrial superoxide can extend lifespan, and antioxidant treatment abolishes the effect. The same logic explains why antioxidant supplementation can blunt some of the adaptations to exercise training.

Why the reversal matters

The failure of antioxidants is biogerontology's clearest case of a mechanistically appealing theory that did not survive intervention studies. It is the standard example cited against reasoning from plausible mechanism to expected benefit, and it is why the field now insists on lifespan and function endpoints instead of damage markers.

§mtDNA mutation and heteroplasmy

Each cell carries many mitochondrial genomes, so mutations exist as a mixture with wild-type copies, a condition called heteroplasmy. A biochemical defect usually appears only when the mutant load in a cell exceeds a threshold, commonly placed between roughly 60 and 90 percent depending on the mutation and tissue. In aging tissue the average mutation burden across all copies stays low. What rises is the number of individual cells that have crossed the threshold through clonal expansion of a single mutant lineage.

These mutations were long assumed to originate in oxidative lesions. Deep sequencing of aged human brain instead found a mutational spectrum dominated by transitions, consistent with errors made by the mitochondrial polymerase during replication.⁵ Mice engineered with a proofreading-deficient version of that polymerase do age prematurely, but they carry mutation loads far above anything seen in normal aging. The model therefore shows that enough mtDNA damage causes an aging-like phenotype; it does not show that mtDNA damage causes normal aging.

§Quality control

Damaged mitochondria are removed by mitophagy, a selective branch of Autophagy. The best-characterized route depends on PINK1, which accumulates on depolarized mitochondria and recruits the ubiquitin ligase Parkin. Receptor-mediated routes using BNIP3, NIX and FUNDC1 operate in parallel and dominate in some tissues. PINK1 and Parkin are both mutated in familial early-onset Parkinson's disease, the strongest human evidence that failing mitochondrial quality control causes degeneration in a specific cell population.

Mitophagy is coupled to mitochondrial dynamics: fission separates damaged segments for disposal, and fusion allows complementation between genomes. Markers of mitophagic flux decline with age in several model organisms, which is part of the reason "disabled macroautophagy" was added as a separate hallmark in 2023. Whether mitophagy declines with age in human tissue is harder to establish, since flux cannot be measured directly in a living person. The same measurement barrier limits biomarker development generally.

§Interventions

Exercise remains the most reliable stimulus of mitochondrial biogenesis and the only intervention with strong human functional evidence. Among drugs and supplements, urolithin A, a gut metabolite of ellagitannins, induces mitophagy in preclinical models and has been tested in humans. Randomized trials in middle-aged and in older adults have reported modest improvements in measures of muscle endurance without clear gains in aerobic capacity.⁶⁷ NAD⁺ precursors are promoted partly on mitochondrial grounds; they raise blood NAD⁺ reliably but have shown little functional benefit. Elamipretide, a peptide that binds cardiolipin in the inner membrane, did not meet its primary endpoint in a phase 3 trial in primary mitochondrial myopathy, though development has continued in narrower indications.

Dietary restriction and Rapamycin both alter mitochondrial turnover, and part of their effect is attributed to better quality control rather than to reduced damage. Mitochondrial-derived peptides such as humanin and MOTS-c have been proposed as signals linking mitochondrial state to organismal metabolism; the human data are observational.

§Transfer, replacement, and editing

Three approaches try to change mitochondria instead of supporting them. In autologous mitochondrial transplantation, mitochondria isolated from a patient's own muscle are injected into ischaemic heart tissue. It has been performed in small paediatric case series at a single centre, with encouraging but uncontrolled results. Mitochondrial replacement in the germline transfers nuclear material into a donor egg so that pathogenic mtDNA is not passed on, and it is legal in a small number of jurisdictions. Editing mtDNA directly is complicated because guide RNAs are not imported into mitochondria, which rules out standard CRISPR approaches. Base editors built from a bacterial toxin that acts on double-stranded DNA have installed specific mtDNA edits in cells and mice, and they are the leading route to a genetic intervention on the mitochondrial genome.

Whether any of this addresses aging, as opposed to specific mitochondrial diseases, is unresolved. Even in old muscle, the clonal expansion that produces cytochrome-oxidase-negative fibres affects a minority of cells, and no one has shown that correcting it restores organ-level function in an aged mammal. The gap between a well-documented molecular lesion and a demonstrated contribution to functional decline is the standing problem for this hallmark, and it applies with equal force to senescence and proteostasis as causal accounts.

§See also

• Hallmarks of aging
• Autophagy
• NAD+ precursors
• Mitochondrial replacement therapy
• Inflammaging
• Exercise as a geroprotector

§References